Novel PLA2G4C polymorphism as a molecular diagnostic assay for 19q loss in human gliomas

Christian Hartmann, Loki Johnk, Hikaru Sasaki, Robert Brian Jenkins, David N. Louis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

PLA2G4C, encoding cytosolic phospholipase A2-γ (cPLA2-γ), is a 17-exon gene located on chromosome 19q13.3 within the putative glioma tumor suppressor gene region. Given the clinical importance of assessing 1p and 19q loss in human gliomas, the development of convenient and practical assays for detecting allelic loss is of considerable priority in neuro-oncology. We report a minisatellite polymorphism in the untranslated region of exon 1, with allelic variants that have one, two or three 27-bp repeats. The polymorphism is informative in 55.7% of a reference population, and accurately detects allelic loss of 19q in human gliomas. This novel marker offers distinct advantages for assessing 19q status in malignant gliomas. The relatively large size of the repeats allows detection of allelic variants with standard ethidium bromide-stained agarose gels and the PLA2G4C marker is the closest polymorphism to the smallest common deletion area in the putative glioma tumor suppressor gene region. These characteristics suggest that the PLA2G4C polymorphism will be a convenient and practical assay for clinical and research evaluation of 19q status in human gliomas.

Original languageEnglish (US)
Pages (from-to)178-182
Number of pages5
JournalBrain Pathology
Volume12
Issue number2
StatePublished - 2002

Fingerprint

Molecular Pathology
Glioma
Loss of Heterozygosity
Tumor Suppressor Genes
Exons
Cytosolic Phospholipases A2
Untranslated Regions
Minisatellite Repeats
Ethidium
Human Development
Sepharose
Chromosomes
Gels
Population
Genes

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pathology and Forensic Medicine

Cite this

Hartmann, C., Johnk, L., Sasaki, H., Jenkins, R. B., & Louis, D. N. (2002). Novel PLA2G4C polymorphism as a molecular diagnostic assay for 19q loss in human gliomas. Brain Pathology, 12(2), 178-182.

Novel PLA2G4C polymorphism as a molecular diagnostic assay for 19q loss in human gliomas. / Hartmann, Christian; Johnk, Loki; Sasaki, Hikaru; Jenkins, Robert Brian; Louis, David N.

In: Brain Pathology, Vol. 12, No. 2, 2002, p. 178-182.

Research output: Contribution to journalArticle

Hartmann, C, Johnk, L, Sasaki, H, Jenkins, RB & Louis, DN 2002, 'Novel PLA2G4C polymorphism as a molecular diagnostic assay for 19q loss in human gliomas', Brain Pathology, vol. 12, no. 2, pp. 178-182.
Hartmann, Christian ; Johnk, Loki ; Sasaki, Hikaru ; Jenkins, Robert Brian ; Louis, David N. / Novel PLA2G4C polymorphism as a molecular diagnostic assay for 19q loss in human gliomas. In: Brain Pathology. 2002 ; Vol. 12, No. 2. pp. 178-182.
@article{9b700e5997774441bd06fabd015aef83,
title = "Novel PLA2G4C polymorphism as a molecular diagnostic assay for 19q loss in human gliomas",
abstract = "PLA2G4C, encoding cytosolic phospholipase A2-γ (cPLA2-γ), is a 17-exon gene located on chromosome 19q13.3 within the putative glioma tumor suppressor gene region. Given the clinical importance of assessing 1p and 19q loss in human gliomas, the development of convenient and practical assays for detecting allelic loss is of considerable priority in neuro-oncology. We report a minisatellite polymorphism in the untranslated region of exon 1, with allelic variants that have one, two or three 27-bp repeats. The polymorphism is informative in 55.7{\%} of a reference population, and accurately detects allelic loss of 19q in human gliomas. This novel marker offers distinct advantages for assessing 19q status in malignant gliomas. The relatively large size of the repeats allows detection of allelic variants with standard ethidium bromide-stained agarose gels and the PLA2G4C marker is the closest polymorphism to the smallest common deletion area in the putative glioma tumor suppressor gene region. These characteristics suggest that the PLA2G4C polymorphism will be a convenient and practical assay for clinical and research evaluation of 19q status in human gliomas.",
author = "Christian Hartmann and Loki Johnk and Hikaru Sasaki and Jenkins, {Robert Brian} and Louis, {David N.}",
year = "2002",
language = "English (US)",
volume = "12",
pages = "178--182",
journal = "Brain Pathology",
issn = "1015-6305",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Novel PLA2G4C polymorphism as a molecular diagnostic assay for 19q loss in human gliomas

AU - Hartmann, Christian

AU - Johnk, Loki

AU - Sasaki, Hikaru

AU - Jenkins, Robert Brian

AU - Louis, David N.

PY - 2002

Y1 - 2002

N2 - PLA2G4C, encoding cytosolic phospholipase A2-γ (cPLA2-γ), is a 17-exon gene located on chromosome 19q13.3 within the putative glioma tumor suppressor gene region. Given the clinical importance of assessing 1p and 19q loss in human gliomas, the development of convenient and practical assays for detecting allelic loss is of considerable priority in neuro-oncology. We report a minisatellite polymorphism in the untranslated region of exon 1, with allelic variants that have one, two or three 27-bp repeats. The polymorphism is informative in 55.7% of a reference population, and accurately detects allelic loss of 19q in human gliomas. This novel marker offers distinct advantages for assessing 19q status in malignant gliomas. The relatively large size of the repeats allows detection of allelic variants with standard ethidium bromide-stained agarose gels and the PLA2G4C marker is the closest polymorphism to the smallest common deletion area in the putative glioma tumor suppressor gene region. These characteristics suggest that the PLA2G4C polymorphism will be a convenient and practical assay for clinical and research evaluation of 19q status in human gliomas.

AB - PLA2G4C, encoding cytosolic phospholipase A2-γ (cPLA2-γ), is a 17-exon gene located on chromosome 19q13.3 within the putative glioma tumor suppressor gene region. Given the clinical importance of assessing 1p and 19q loss in human gliomas, the development of convenient and practical assays for detecting allelic loss is of considerable priority in neuro-oncology. We report a minisatellite polymorphism in the untranslated region of exon 1, with allelic variants that have one, two or three 27-bp repeats. The polymorphism is informative in 55.7% of a reference population, and accurately detects allelic loss of 19q in human gliomas. This novel marker offers distinct advantages for assessing 19q status in malignant gliomas. The relatively large size of the repeats allows detection of allelic variants with standard ethidium bromide-stained agarose gels and the PLA2G4C marker is the closest polymorphism to the smallest common deletion area in the putative glioma tumor suppressor gene region. These characteristics suggest that the PLA2G4C polymorphism will be a convenient and practical assay for clinical and research evaluation of 19q status in human gliomas.

UR - http://www.scopus.com/inward/record.url?scp=0036202238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036202238&partnerID=8YFLogxK

M3 - Article

C2 - 11958371

AN - SCOPUS:0036202238

VL - 12

SP - 178

EP - 182

JO - Brain Pathology

JF - Brain Pathology

SN - 1015-6305

IS - 2

ER -